UPB ▼ -0.5% - Upstream Bio, Inc. $UPB - Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026 Upstream Bio shares declined 0.5% today as the company presented Phase 2 data for its experimental asthma treatment verekitug at the ERS Congress. The oral presentation of results from the VALIANT trial provided investors with a detailed look at the drug's efficacy and safety profile in severe asthma patients, though the modest decline suggests the market may have had higher expectations or found elements of the data less compelling than anticipated. 08-SEP-2026 03:30 AM ET